Allosteric inhibitors against HIV-1 reverse transcriptase: Design and synthesis of MKC-442 analogues having an ω-functionalized acyclic structure

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 4, 1998, Pages 325-332

  Tanaka, H ^a   Walker, R T ^b   Hopkins, A L ^c   Ren, J ^c   Jones, E Y ^c,d   Fujimoto, K ^a   Hayashi, M ^a   Miyasaka, T ^a   Baba, M ^e   Stammers, D K ^c   Stuart, D I ^c,d  

^a SHOWA UNIVERSITY   (Japan)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Anti HIV activity; HEPT; Hydrogen bonding; MKC 442; NNRTIs; Reverse transcriptase

Indexed keywords

6 BENZYL 1 ETHOXYMETHYL 5 ISOPROPYLURACIL DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDROGEN BOND; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC SITE; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HYDROGEN BONDING; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; URACIL; VIRUS REPLICATION;

EID: 0031820690     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, Nakashima H, Perno C-F, Walker RT & Miyasaka T (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochemical and Biophysical Research Communications 165:1375-1381.
2. Baba M, Shigeta S, Yuasa S, Takashima H, Sekiya K, Ubasawa M, Tanaka H, Miyasaka T, Walker RT & De Clercq E (1994) Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobial Agents and Chemotherapy 38:688-692.
3. Brennan TM, Taylor DL, Bridges CG, Leyda JP & Tyms AS (1995) The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Research 26:173-187.
4. De Clercq E (1996) Non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus type 1 infections: strategies to overcome drug resistance development. Medical Research Reviews 16:125-157.
5. Esnouf R, Ren J, Hopkins A, Ross C, Jones EY, Stammers D & Stuart D (1997) Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U90152 explain resistance mutations for this non-nucleoside inhibitor. Proceedings of the National Academy of Sciences, USA 94:3984-3989.
6. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK & Stuart DI (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. Journal of Medicinal Chemistry 39:1589-1600.
7. Jones T (1985) Interactive computer graphics: FRODO. Methods in Enzymology 115:157-171.
8. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. Journal of Applied Crystallography 24:946-950.
9. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih C-K, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
10. Miyasaka T, Tanaka H, Baba M, Hayakawa H, Walker RT, Balzarini J & De Clercq E (1989) A new lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry 32: 2507-2509.
11. Miyoshi I, Taguchi H, Kubonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y & Akagi T (1982) Type C virus producing cell lines derived from adult T cell leukemia. Gann Monographs 28:219-228.
12. Pauwels R, De Clercq E, Desmyter J, Balzarini J, Goubau P, Herdewijn P, Vanderhaeghe H & Vandeputte M (1987) Sensitive and rapid assay on MT-4 cells for the detection of antiviral compounds against the AIDS virus. Journal of Virological Methods 16:171-185.
13. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20:309-321.
14. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers, A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E & Janssen PAJ (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
15. Tanaka H, Hayakawa H & Miyasaka T (1993) Lithiation chemistry of uridine derivatives: access to a new anti-HIV-1 lead. In Nucleosides and Nucleotides as Antitumor and Antiviral Agents, pp. 23-53. Edited by CK Chu & DC Baker. New York: Plenum Press.
16. Tanaka H, Takashima H, Ubasawa M, Sekiya K, Inouye N, Baba M, Shigeta S, Walker RT, De Clercq E & Miyasaka T (1995) Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. Journal of Medicinal Chemistry 38:2860-2865.
17. Wang H & Ben-Naim A (1996) A possible involvement of solvent-induced interactions in drug design. Journal of Medicinal Chemistry 39:1531-1539.
18. Yuasa S, Sadakata Y, Takashima H, Sekiya K, Inouye N, Ubasawa M & Baba M (1993) Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Molecular Pharmacology 44:895-900.